At this year's Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), Nanobiotix will be providing encore presentations of updated data from its phase I head and neck cancer study, phase I immunotherapy study and phase III soft tissue sarcoma study.
Founded in 1980, ESTRO is a non-profit scientific organization that aims to further reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. The congress will take place in Madrid, Spain from August 27 to 31 and the entire program will be available online as well.
The European Society for Medical Oncology (ESMO) Annual Meeting will be virtual this year from 18th to 22nd September. This conference is the opportunity for medical oncologists and other oncology professionals from the many related fields to come together. Pr. Le Tourneau and Pr. De Baere will be there presenting datas.
